SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Lifyorli

CORT·CORCEPT THERAPEUTICS INC
BULLISH
Drug Impact Rating7/10
Trial phase
Approved
Time to market
Lifyorli is already approved and commercially available in the U.S. for platinum-resistant ovarian cancer (approved March 25, 2026). A decision on the Cushing's syndrome indication is expected by December 17, 2026. A Marketing Authorization Application (MAA) is also under review by the European Medicines Agency.
Why 7/10
The next hard, dated catalyst is the FDA PDUFA target action date of December 17, 2026 for relacorilant's NDA resubmission in Cushing's syndrome, approximately 6 weeks away. This is a major label-expansion binary for a drug that is already approved and generating revenue, at a company with other commercial products (Korlym) and pipeline programs, so it scores a 7 rather than higher.
Actionable Insight BULLISH

The next major catalyst is the December 17, 2026 PDUFA decision on relacorilant's NDA resubmission for Cushing's syndrome. An approval would open a large endocrinology market (currently served by Korlym, which generated ~$498M in the first nine months of 2026) and could significantly expand the drug's total addressable market beyond the already-approved ovarian cancer indication. A second CRL would be a major setback for the Cushing's franchise.

Price Chart

Loading chart...

Executive Summary

Lifyorli (relacorilant) is Corcept Therapeutics' second commercial drug and the first FDA-approved selective glucocorticoid receptor antagonist (SGRA). It was approved on March 25, 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer, based on the Phase 3 ROSELLA trial showing a 35% reduction in risk of death. The launch is accelerating rapidly, with Q3 2026 revenue of $91.4 million (up 92% quarter-over-quarter). The next major catalyst is the December 17, 2026 PDUFA date for relacorilant's NDA resubmission in Cushing's syndrome, a large endocrinology market where Corcept already sells Korlym (mifepristone). The stock has pulled back sharply from its 52-week high amid a broader market selloff, but analyst consensus remains strongly bullish with a mean price target of $141.

How It Works

Lifyorli (relacorilant) is a selective glucocorticoid receptor antagonist (SGRA). It blocks the activity of the hormone cortisol by competing for binding at the glucocorticoid receptor. In cancer, cortisol signaling can help tumors resist chemotherapy, so blocking it makes cancer cells more sensitive to treatment. In Cushing's syndrome, the drug reduces the harmful effects of excess cortisol in the body.

Trial Status

Lifyorli was approved by the FDA on March 25, 2026 based on the Phase 3 ROSELLA trial (N=381) in platinum-resistant ovarian cancer, which met its primary endpoint of overall survival. The drug was added to NCCN Guidelines as a preferred regimen. A separate Phase 3 GRACE trial in Cushing's syndrome supported an NDA resubmission now under FDA review with a PDUFA date of December 17, 2026. The company is also exploring relacorilant in other solid tumors and metabolic indications.

The Two-Sided Case

▲ Bull Case6
Lifyorli is the first and only FDA-approved selective glucocorticoid receptor antagonist (SGRA), a novel mechanism that enhances chemotherapy sensitivity by blocking cortisol signaling in tumor cells.
The drug's commercial launch is accelerating rapidly: Q3 2026 Lifyorli revenue was $91.4 million, up 92% from $47.6 million in Q2 2026, with total company revenue of $340.5 million beating analyst estimates.
The pivotal ROSELLA Phase 3 trial showed a 35% reduction in risk of death, and the regimen was added to NCCN Guidelines as a preferred treatment option.
The December 17, 2026 PDUFA for relacorilant in Cushing's syndrome represents a major label expansion opportunity into a large endocrinology market currently served by Korlym ($373.5M in H1 2026).
Analyst consensus is strongly bullish: 7 Buy, 3 Strong Buy ratings with a mean price target of $141 (approximately 97% upside from the current $71.63 price).
Multiple institutional investors added or doubled positions in Q2 and Q3 2026, including Allspring, Bank of America, Nuveen, and Fuller & Thaler.
▼ Bear Case5
The FDA issued a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome in December 2025, and the resubmission may face similar concerns about the GRACE trial data or liver safety signals.
Insiders have been selling substantial amounts of stock in October and November 2026, with multiple executives exercising options and selling shares at prices between $80-$116.
The stock has fallen sharply from its 52-week high of $126.38 to $71.63, a decline of over 43%, suggesting significant de-risking or concerns about the Cushing's PDUFA outcome.
Several institutional investors trimmed or exited positions in Q2 2026, including Jane Street (near-exit, -98.5%), Citadel (-57.1%), and Millennium (-72.7%).
Lifyorli faces competition from established chemotherapies and newer targeted agents in platinum-resistant ovarian cancer, and its combination with nab-paclitaxel carries safety warnings for neutropenia, severe infections, and adrenal insufficiency.

Upcoming Catalysts

  • December 17, 2026: FDA PDUFA target action date for relacorilant NDA resubmission in Cushing's syndrome (hypercortisolism)
  • EMA decision on Marketing Authorization Application (MAA) for relacorilant in platinum-resistant ovarian cancer
  • Potential label expansion data from ongoing trials in other solid tumors and metabolic indications

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CORCEPT THERAPEUTICS INC 8-K CORT ·Originating report

Sources · 11

Hover a chip for the title
1 ir.corcept.com2 fda.gov3 ir.corcept.com4 ir.corcept.com5 nasdaq.com6 ir.corcept.com7 trialfriend.com8 corcept.com9 drugs.com10 lifyorlihcp.com11 zacks.com